RT Journal Article
SR Electronic
T1 Decreased serum levels of the inflammaging marker miR-146a are associated with clinical response to tocilizumab in COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.11.20151365
DO 10.1101/2020.07.11.20151365
A1 Sabbatinelli, Jacopo
A1 Giuliani, Angelica
A1 Matacchione, Giulia
A1 Latini, Silvia
A1 Laprovitera, Noemi
A1 Pomponio, Giovanni
A1 Ferrarini, Alessia
A1 Baroni, Silvia Svegliati
A1 Pavani, Marianna
A1 Moretti, Marco
A1 Gabrielli, Armando
A1 Procopio, Antonio Domenico
A1 Ferracin, Manuela
A1 Bonafè, Massimiliano
A1 Olivieri, Fabiola
YR 2020
UL http://medrxiv.org/content/early/2020/11/21/2020.07.11.20151365.abstract
AB Current COVID-19 pandemic poses an unprecedented threat to global health and healthcare systems. The most amount of the death toll is accounted by old people affected by age-related diseases that develop a hyper-inflammatory syndrome. In this regard, we hypothesized that COVID-19 severity may be linked to inflammaging. Here, we examined 30 serum samples from patients enrolled in the clinical trial NCT04315480 assessing the clinical response to a single-dose intravenous infusion of the anti-IL-6 receptor drug Tocilizumab (TCZ) in COVID-19 patients with multifocal interstitial pneumonia.In these serum samples, as well as in 29 age- and gender-matched healthy control subjects, we assessed a set of microRNAs that regulate inflammaging, i.e. miR-146a-5p, miR-21-5p, and miR-126-3p, which were quantified by RT-PCR and Droplet Digital PCR.We showed that COVID-19 patients who did not respond to TCZ have lower serum levels of miR-146a-5p after the treatment (p=0.007). Among non-responders, those with the lowest serum levels of miR-146a-5p experienced the most adverse outcome (p=0.008). Our data show that a blood-based biomarker, such as miR-146a-5p, can provide clues about the molecular link between inflammaging and COVID-19 clinical course, thus allowing to better understand the use of biologic drug armory against this worldwide health threat.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04315480Funding StatementThis study was supported by grants from Universita' Politecnica delle Marche (RSA grant to FO and ADP) and Italian Ministry of Health ('Ricerca corrente' grant to IRCCS INRCA). MF lab is supported by Italian Association for Cancer Research (AIRC) and Pallotti Fund. MB is supported by Pallotti Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Regional Institutional Review Board (Comitato Etico Regione Marche).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding authors upon reasonable request.